Chemical Nameteprotumumab-trbw
Dosage FormInjectable (intravenous; 500 mg/vial)
Drug ClassMonoclonal antibodies
CompanyHorizon Therapeutics Ireland
Approval Year2020


  • Tepezza is indicated for the treatment of Thyroid Eye Disease.
Last updated on 10/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tepezza (teprotumumab-trbw) Prescribing Information2020Horizon Therapeutics USA Inc., Lake Forest, IL
Document TitleYearSource
Teprotumumab for the treatment of active thyroid eye disease2020The New England Journal of Medicine